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Andrew Barleben, MD, MPH, Los Angeles, Calif
Intervention may be necessary in up to one-third of patients with endoleaks after endovascular aortic aneurysm repair
(EVAR). Perigraft arterial sac embolization (PASE) to induce aneurysm thrombosis was performed by intrasac injection
of thrombin and gelfoam slurry. Thirteen patients were treated with PASE since 2006. Eight patients underwent
immediate PASE, and ﬁve patients were treated during surveillance following EVAR. The median follow-up is
23.9 months (range, 2.6-66.1 months) for the entire cohort; 24.4 and 23.1 months for the immediate and delayed group,
respectively. No patients had further aneurysm growth. One (8%) patient maintained stable aneurysm size with
a persistent type II endoleak, and 11 (85%) patients had aneurysm shrinkage. PASE to induce sac thrombosis after EVAR
is an alternative for the treatment of endoleaks. Further study is required to deﬁne optimal patient selection, safety, long-
term efﬁcacy and potential cost-savings of this technique. (J Vasc Surg 2014;59:538-41.)Since 1991 when endovascular aortic aneurysm repair
(EVAR) of infrarenal aortic aneurysms was ﬁrst described,
it has become the preferred alternative to open repair.1
EVAR has demonstrated improved early morbidity and
mortality in comparison to traditional open repair; EVAR
does, however, require more frequent surveillance than
open repair due to the possibility of graft migration,
component separation, limb kinking or occlusion, or endo-
leaks.2 These complications may then necessitate further
intervention.
Consensus is nearly universal regarding the need for
treatment of type I and III endoleaks. Current literature
is nearly unanimous in accepting observation alone for
type II endoleaks (T2Es), with no need for intervention
while aneurysm sac size remains stable or decreases in
size. Should the aneurysm enlarge, the timing of and treat-
ment modalities remain controversial, and there is currently
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://dx.doi.org/10.1016/j.jvs.2013.07.104T2Es occur when there is successful aneurysm sac exclu-
sion, but patent feeding vessels (lumbar, mesenteric, sacral,
or renal arteries) continue to pressurize the aneurysm sac.
T2Es are the most common type, occurring in approxi-
mately 10% to 25% of cases following endograft placement.5
Most will resolve spontaneously, but some will require inter-
vention. This report presents our experience with perigraft
arterial sac embolization (PASE) to induce thrombosis and
resolve acute type I endoleaks or T2Es or chronic T2Es
with aneurysm growth during surveillance after EVAR.
METHODS
This is a single-institution, single-surgeon retrospective
review of all patients who underwent EVAR for abdominal
aneurysms with concomitant PASE (immediate) or as
a separate intervention (delayed) during the surveillance
period. All patients were considered anatomically suitable
candidates for EVAR based on the manufacturer’s instruc-
tion for use. Patients were treated between May 2006 and
February 2012 out of 136 total treated infrarenal aortic or
aortoiliac aneurysms.
PASE was chosen for the immediate group when a type
I endoleak could not be resolved by traditional methods
(re-balloon, proximal extension, or stent) or a brisk type
II endoleak was noted. It was used in a delayed manner
when a persistent T2E was present and associated with
sac growth at a rate of 5 mm in 6 months (or less for larger
aneurysms). Our group is aggressive in resolving type I
endoleaks during EVAR; T2Es are only treated at the index
procedure when they are large.
PASE is performed by simultaneous introduction of an
0.035-inch hydrophilic wire and a stiff, angled 5F catheter,
Table I. Overall patient information
No. %
Patients 13
Immediate PASE 5 38
Delayed PASE 8 62
Average follow-up, months 23.9
Endoleak type
Type Ia 6 46
Type Ib 1 7.6
Type II 5 38
Type III 0 0
Type IV 1 7.6
PASE, Perigraft arterial sac embolization.
Table II. A, Demographics of patients with immediate
perigraft arterial sac embolization (PASE)
Range Average SD
Age, years 68-94 80.6 8.78
Follow-up, days 211-1528 732.38 531.66
Sex No. (%)
Male 6 (75)
Female 2 (25)
SD, Standard deviation.
Table II. B, Patient characteristics with immediate
perigraft arterial sac embolization (PASE)
Concomitant leak No. (%)
Type I 5 (62.5)
Type III 0 (0)
Type IV 0 (0)
Residual T2E 0 (0)
Conversion 0 (0)
Allergic reaction 0 (0)
Mortality 0 (0)
T2E, Type II endoleak.
Table III. A, Demographics of patients with delayed
perigraft arterial sac embolization (PASE)
Range Average SD
Age, years 72-83 78.6 4.3
Time to PASE, days 376-3566 1202.6 1352.43
Follow-up, days 78-1982 693 759.37
Sex No. (%)
Male 5 (100)
Female 0 (0)
SD, Standard deviation.
Table III. B, Patient characteristics with delayed
perigraft arterial sac embolization (PASE)
Concomitant leak No. (%)
Type I 2 (40)
Type III 0 (0)
Type IV 1 (20)
Residual T2E 2 (40)
Conversion 1 (20)
Allergic reaction 0 (0)
Mortality 0 (0)
T2E, Type II endoleak.
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artery and iliac limb of the graft. The wire-catheter combi-
nation is directed into the aneurysm sac preferably toward
the site of the endoleak, which is not always possible.
Access site is preferential but not limited to the side of
primary access in patients who undergo PASE at the time
of endograft implantation. In delayed intervention, access
is selected based on the side with the least apposition
between graft and iliac artery on postoperative computed
tomography (CT). Once catheter access was obtained,
a hand injection of contrast was performed both to deter-
mine catheter location and if a feeding vessel could be visu-
alized (Video 1, online only). Occasionally, the inferior
mesenteric artery was identiﬁed as the responsible vessel,
cannulated via the sac and occluded with coils. Otherwise,
5 to 10 mL of slurry was injected until the sac was largely
ﬁlled with contrast and sac angiograms used to conﬁrm
thrombosis. This slurry consists of thrombin (1000
units/20 mL saline), gelfoam cut into ﬁne pieces and 2
to 4 mL of contrast mixed together by ﬂushing between
two syringes connected by a three-way stopcock (Video 2,
online only).
RESULTS
A total of 13 patients required intervention. All patients
underwent EVAR for abdominal aneurysms, with varying
types of endoleaks and had an average follow-up of
23.9 months (Table I). No patients experienced morbidity
or mortality secondary to endovascular aneurysm repair or
PASE. All attempts at sac access were successful.Immediate PASE. Table II, A and B are overviews of
the main patient characteristics of the eight patients who
underwent PASE during EVAR placement. Patients were
between 68 and 94 years of age (average age, 80.6 years;
standard deviation [SD], 8.78), with the number of
months from the original operation with PASE to follow-
up between 7.0 and 66.0 (mean, 24.4; SD, 17.72). Two
patients (25%) were female and six (75%) were male.
One patient also underwent embolization of a por-
tion of the aneurysm sac using coils, and another
patient underwent embolization of his inferior mesen-
teric artery via PASE. No patients in this group had
endoleaks on follow-up angiogram or surveillance CT
scans (Table III). No patients had a complication,
required conversion to open repair, or suffered aneu-
rysm-related death during follow-up.
Fig. Patient with presumed type II endoleak (T2E) (a) (preop-
erative computed tomography [CT] scan) with conﬁrmed type IV
endoleak intraoperatively (b) (intraoperative photograph).
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patient characteristics of the ﬁve patients who underwent
PASE following EVAR as a separate procedure. These
patients were between 72 and 83 years of age (mean, 78.6;
SD, 4.3). In this group, PASE was performed 12.53 to
118.87 months (mean, 40.09; SD, 45.08) after EVAR.
Patient follow-up in this group ranged from 2.6 to
66.1 months (mean, 23.1; SD, 25.31).
One patient had a residual T2E without sac growth who
we are following. Another patient had a persistent T2E with
sac growth following PASE; however, upon conversion to
open repair, operative ﬁndings documented a type IV endo-
leak (Fig). There was no morbidity or aneurysm-related
death during follow-up.
DISCUSSION
Endoleaks may complicate endovascular treatment of
infrarenal abdominal aortic aneurysms, thus, necessitating
surveillance with contrast-enhanced CT. Intervention after
EVAR secondary to endoleaks is necessary in 11% to 25%
of patients, with the largest portion (40%) secondary to
T2Es.5,7,8
Type I endoleaks occur in 0% to 10% of all EVARs.
These require intervention; by deﬁnition, the aneurysm
sac remains pressurized by the arterial system, thus, por-
tending an unchanged risk in rupture. The natural historyof T2Es has yet to be accurately delineated. In some cases,
there is resolution of the endoleak (30%-100%) with subse-
quent decrease in aneurysm size and by extension,
decreased risk of rupture. Other aneurysms remain stable
in size despite endoleak, and others continue to grow.5,6
Endoleaks are not always visualized, thus, there is a need
for surveillance to identify aneurysm growth following
EVAR, detect endoleaks, and determine if intervention is
necessary.
There is a general consensus that intervention is pre-
ferred for T2Es that lead to sac enlargement. Jones et al
found that the persistent presence of endoleaks was associ-
ated with an increased risk of adverse outcomes, sac
growth, reintervention rate, and rupture, suggesting the
need for more frequent surveillance or a more aggressive
approach to reintervention.3 Other studies have found
that risk factors for patients with T2E requiring treatment
include the combination of patent inferior mesenteric
artery and either more than six patent lumbar arteries,
a maximum luminal diameter of greater than 3.0 cm, or
age greater than 70 years.9 We believe that treatment of
persistent T2Es should be considered in large aneurysms
(>8 cm) with these risk factors.
Methods of intervention ranging from additional
ballooning, placement of aortic or iliac cuffs, balloon-
expandable stents, and transarterial or coil embolization
to translumbar sac embolization have been well docu-
mented in radiologic and surgical literature.6,10-12 Aneu-
rysm sac embolization traditionally involves an angiogram
of the repaired aneurysm and selective angiograms of celiac,
mesenteric, and hypogastric arteries to identify sources of
the T2E. These methods have excellent results but do still
require long-term follow-up.4 Treatment of T2E via trans-
arterial or translumbar approaches may not, however, be
successful with respect to aneurysm-related mortality but
may nonetheless be useful in the diagnosis of other types
of endoleaks.13 Other techniques include transperitoneal
lumbar artery ligation, both open and laparoscopically, as
well as the introduction of novel substances into the sac
for induction of thrombosis.14-18 More recently, transcaval
aneurysm sac access has been used successfully in four of six
patients to coil and selectively inject thrombin for treat-
ment of T2Es.19
Aneurysm sac “thrombinization” used preemptively
has also been studied in an attempt to reduce the rate of
endoleak development. Ronsivalle et al analyzed several
hundred patients who underwent intraoperative sac embo-
lization with ﬁbrin glue and coils.20 The authors noted that
their rates of type I endoleak and T2E went from 2.6% to
1.1% and 15% to 2.2%, respectively, with no procedure-
related complications. Similar results with selective ﬁbrin
glue injection for residual type I endoleak alone have
been recently reported.21
This report presents our experience with PASE in
select patients performed immediately or during the
surveillance period following EVAR. PASE was used for
the treatment for type I endoleak, T2E, and patients
with a combination of these endoleaks when standard
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T2E include immediate evaluation and conﬁrmation of
resolution and treatment of both inﬂow and outﬂow
culprit vessels. It also avoids use of radiopaque material
as is customary in translumbar sac injection, which inter-
feres with follow-up surveillance CT. In this limited expe-
rience, there were no complications of spinal cord
paralysis (a theoretical complication), distal embolization,
or anaphylaxis following intrasac infusion of thrombin and
gelfoam slurry.
There may be a role for intrasac injection for induction
of sac thrombosis in prevention and treatment endoleaks
after EVAR. Further experience is needed to establish
optimal patient selection, safety, long-term efﬁcacy, and
potential cost savings of this approach.
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